and you are saying these factors won't influence the risk-on/risk-off environment, and thus biotech stocks
now, your just being silly. So, you deny that investors who manipulate stocks don't use the headwinds and tailwinds of other news?
You don't think the orchestrated 80 percent drop in this stock wasn't fueled by the risk off environment
6 months or a year?
They are getting them while they can, before the bog buyout
wasn't one of the bashers on twits outed as a linzess sales rep?
nice to hear from you. We are in the last 6 months of the 5 yearmarathon, we need some risk on environment, and from what I hear, Clinton for president
yearly meeting was supposed to be business as usual, no major issues, has that changed
with Ron's pole buried in you, and the screaming, you can't bury anything. besides, you are only tall enough to get to a Bassett hound. does you queef in the end
CPI-431-32 is a next-generation non-immunosuppressive cyclophilin inhibitor shown to have best-in-class potency against hepatitis B virus (HBV) and a significantly larger selective index compared to previously known cyclophilin inhibitors. It is anticipated that this large selective index will provide a meaningful degree of clinical utility in the treatment of chronic HBV infection. Upon completion of the merger, Ciclofilin's Founder and CEO Robert Foster, Pharm.D., Ph.D., will join ContraVir in the role of Chief Scientific Officer, and will continue leading the development of CPI-431-32 into IND-enabling studies.
how does someone with autism blow bones? we won't know until you tell us Ron, but I heard you are average, but you get points for humming while you do the asain